Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Minoryx Therapeutics

Request full access

Clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs

Mataró, SpainFounded 2011Biotech & Life Sciences

About Minoryx Therapeutics

Minoryx Therapeutics is a biotechnology startup dedicated to discovering and developing innovative treatments for severe, rare diseases of the central nervous system (CNS). These conditions, often referred to as orphan diseases, have high unmet medical needs, meaning there are few or no effective treatments available. The company is headquartered in Gosselies, Charleroi, Belgium.

Minoryx primarily targets patients suffering from life-threatening neurodegenerative disorders. Their leading program focuses on a compound called leriglitazone, a novel and selective PPAR gamma agonist. This compound is currently in clinical development for multiple orphan CNS disorders, with its primary indication being X-linked Adrenoleukodystrophy (X-ALD), a severe neurodegenerative disease.

The company operates in the biopharmaceutical market, which involves the research, development, and commercialization of drugs. Minoryx's business model revolves around the development and licensing of its proprietary treatments. They generate revenue through partnerships and licensing agreements with other pharmaceutical companies. For instance, Minoryx has an exclusive license agreement with Sperogenix Therapeutics to develop and commercialize leriglitazone in mainland China, Hong Kong, and Macau.

Minoryx has also received significant financial backing to support its research and development efforts. The European Investment Bank has provided substantial funding, and the company has received a fast-track designation from the US FDA for leriglitazone in the treatment of X-ALD. This designation helps expedite the development and review process for drugs that treat serious conditions and fill an unmet medical need.

In summary, Minoryx Therapeutics is at the forefront of developing breakthrough therapies for rare CNS diseases, aiming to bring new hope to patients with limited treatment options.

Source: Dealroom company data

At a glance

Status
Operational
Employees
33
Open positions
None listed
Dealroom signal
69.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Genetics and genomics, Spinout, Disease, Sustainable Development Goals, Biotech and Pharma, Hard Tech, Seal of Excellence EC, Horizon Europe
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Jul 2017
Capital deployed
$0
Preferred round
CORPORATE SPINOUT

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jul 2025 $30M — Undisclosed ↗
SERIES COther financing May 2022 $26M $102M Ysios Capital · FundPlus · Criteria Venture Tech · CDTI Innvierte ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Minoryx Therapeutics website traffic

Latest recorded traffic for Minoryx Therapeutics is 5.3K monthly website visits, up 10.4% over the last three months. Minoryx Therapeutics's team grew 3.1% over the past year.

Latest monthly visits5.3K 3-month web change+10.4% 1-year team growth+3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Minoryx Therapeutics in the Mataró ecosystem

Live from Dealroom

The Minoryx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • European Innovation Council
  • European Investment Bank

Series A10 investors entered at this stage

Series B and later2 investors entered at this stage

  • Columbus Venture Partners
  • CDTI Innvierte

Other known investors2 additional known investors

  • ICREA
  • University of Barcelona
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Minoryx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.